PRAMLINTIDE ACETATE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18998755 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021332s007_S016.pdf

Pramlintide is an analog of human amylin. Amylin is co-secreted with insulin from pancreatic beta cells and acts centrally to slow gastric emptying, suppress postprandial glucagon secretion, and decrease food intake. These actions complement those of insulin to regulate blood glucose concentrations. Amylin is relatively deficient in patients with type 2 diabetes, depending on the severity of beta-cell secretory failure, and is essentially absent in patients with type 1 diabetes. Through mechanisms similar to those of amylin, pramlintide improves overall glycemic control, reduces postprandial glucose levels, and reduces bodyweight in patients with diabetes using mealtime insulin. SYMLIN® (pramlintide acetate) is indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 1 diabetes 3 Sources: https://www.drugs.com/pro/symlin.html	Palliative		Approved 8429	SYMLIN Approved Use SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. Launch Date 2005

Sample Use Guides

In Vivo Use Guide

•Upon initiation of SYMLIN® (pramlintide acetate), reduce mealtime insulin dose by 50%. Monitor glucoses frequently and individualize subsequent insulin dose adjustments. •Type 1 Diabetes: Start at 15 mcg subcutaneously before major meals. Increase in 15 mcg increments to a maximum premeal dose of 30 or 60 mcg; if not tolerated, reduce to 30 mcg, as tolerated. •Type 2 Diabetes: Start at 60 mcg subcutaneously before major meals then increase to 120 mcg before meals, as tolerated. •Wait at least 3 days between dose titrations to minimize nausea.

Route of Administration: Other

Substance Class	Protein Created by `admin` on `Sat Dec 16 00:24:18 GMT 2023` Edited by `admin` on `Sat Dec 16 00:24:18 GMT 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	726I6TE06G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PRAMLINTIDE ACETATE

Official Name

English

PRAMLINTIDE ACETATE [ORANGE BOOK]

Common Name

English

AC0-137

Code

English

PRAMLINTIDE ACETATE HYDRATE

Common Name

English

PRAMLINTIDE ACETATE [MART.]

Common Name

English

SYMLIN

Brand Name

English

Pramlintide acetate [WHO-DD]

Common Name

English

TRIPRO-AMYLIN ACETATE HYDRATE

Common Name

English

PRAMLINTIDE ACETATE [USAN]

Common Name

English

LYS-CYS-ASN-THR-ALA-THR-CYS-ALA-THR-GLN-ARG-LEU-ALA-ASN-PHE-LEU-VAL-HIS-SER-SER-ASN-ASN-PHE-GLY-PRO-ILE-LEU-PRO-PRO-THR-ASN-VAL-GLY-SER-ASN-THR-TYR-NH2 ACETATE HYDRATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29711